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ABSTRACT
Objectives To develop and cross- validate a 
multivariable clinical prediction model to identify invasive 
bacterial infections (IBI) and to identify patient groups 
who might benefit from new biomarkers.
Design Prospective observational study.
Setting 12 emergency departments (EDs) in 8 
European countries.
Patients Febrile children aged 0–18 years.
Main outcome measures IBI, defined as bacteraemia, 
meningitis and bone/joint infection. We derived and 
cross- validated a model for IBI using variables from the 
Feverkidstool (clinical symptoms, C reactive protein), 
neurological signs, non- blanching rash and comorbidity. 
We assessed discrimination (area under the receiver 
operating curve) and diagnostic performance at different 
risk thresholds for IBI: sensitivity, specificity, negative and 
positive likelihood ratios (LRs).
Results Of 16 268 patients, 135 (0.8%) had an IBI. 
The discriminative ability of the model was 0.84 (95% 
CI 0.81 to 0.88) and 0.78 (95% CI 0.74 to 0.82) in 
pooled cross- validations. The model performed well for 
the rule- out threshold of 0.1% (sensitivity 0.97 (95% CI 
0.93 to 0.99), negative LR 0.1 (95% CI 0.0 to 0.2) and 
for the rule- in threshold of 2.0% (specificity 0.94 (95% 
CI 0.94 to 0.95), positive LR 8.4 (95% CI 6.9 to 10.0)). 
The intermediate thresholds of 0.1%–2.0% performed 
poorly (ranges: sensitivity 0.59–0.93, negative LR 
0.14–0.57, specificity 0.52–0.88, positive LR 1.9–4.8) 
and comprised 9784 patients (60%).
Conclusions The rule- out threshold of this model 
has potential to reduce antibiotic treatment while the 
rule- in threshold could be used to target treatment in 
febrile children at the ED. In more than half of patients 
at intermediate risk, sensitive biomarkers could improve 
identification of IBI and potentially reduce unnecessary 
antibiotic prescriptions.
INTRODUCTION
Children presenting at the emergency depart-
ment (ED) still die from treatable invasive bacterial 
infections (IBI) due to delayed or missed diagnosis.1–3 
For not missing one child with IBI, antibiotics 
are prescribed in children with self- limiting viral 
What is already known on this topic?
 ► In children, distinction between invasive 
bacterial and self- limiting infections on only 
clinical symptoms is unreliable leading to 
overuse of antibiotics on the one hand, but to 
missed invasive bacterial infections in others.
 ► Several clinical prediction models including 
biomarkers have been developed to help 
decision making by risk prediction of patients at 
high risk or low risk for bacterial infections, but 
none predicts the outcome invasive bacterial 
infections in older children or includes children 
with chronic conditions.
What this study adds?
 ► We derived and externally validated a clinical 
prediction model based on clinical predictors 
from the Feverkidstool (clinical symptoms, 
C reactive protein) and non- blanching rash, 
neurological symptoms and comorbidity, to 
early recognise invasive bacterial infections 
with data from a large observational European- 
wide study of febrile children aged 0–18 years.
 ► The rule- out threshold of this model could 
reduce antibiotic prescription and invasive 
diagnostics, while the rule- in threshold could 
be useful to target early treatment for invasive 
bacterial infections.
 ► In more than half of the patients at 
intermediate risk, sensitive new biomarkers 
could reduce diagnostic uncertainty and 
improve identification of invasive bacterial 
infections.
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infections.4 The distinction between bacterial and viral infections 
based solely on clinical signs and symptoms is unreliable. Although 
C reactive protein (CRP) and procalcitonin are currently used as 
markers for bacterial infections, they measure non- specific inflam-
mation and immunological responses. Recent studies focus on 
proteomic and transcriptomic approaches for finding new discrim-
inators of bacterial and viral infections.5–8 Due to costs and limited 
resources, it is not feasible to apply new biomarkers to all febrile 
children. Therefore, prediction models are needed to identify risk 
groups where biomarkers can improve diagnosis.
Clinical prediction models that include clinical signs and CRP 
or procalcitonin have been developed to assist decision making 
in treatment of febrile children,9–15 and have focused on young 
infants to differentiate between patients at high risk or low risk 
for IBI (bacteraemia, meningitis, bone/joint infections). No clinical 
prediction models for IBI exists for older children who are also at 
risk for IBI.16 17 The Feverkidstool, developed for children aged 
<16 years, predicts risks for pneumonia and other serious bacterial 
infections which besides IBIs also includes bacterial infections of 
the urinary tract, gastrointestinal tract and soft tissue.
Although the Feverkidstool is extensively validated, the original 
population only included 21 IBI cases and important predictors for 
IBI such as non- blanching rash or neurological symptoms were not 
included. Several models yet exist for prediction of bacterial pneu-
monia and the impact of the original Feverkidstool on antibiotic 
use in respiratory tract infections is proven.18 Therefore, another 
model for bacterial pneumonia is not required. Furthermore, 
prediction of urinary tract infections may be less relevant as sensi-
tive laboratory tests (urinalysis) are readily available for accurate 
diagnosis at ED visit. In addition, the Feverkidstool is developed in 
previous healthy children and is therefore not applicable for chil-
dren with chronic conditions with higher risk of IBI. Hence, a new 
tool is required for early risk assessment of IBI in febrile children 
including all age ranges (0–18 years) and chronic conditions.
We aim (1) to derive and cross- validate a clinical predic-
tion model including CRP to identify IBIs in febrile children 
presenting to different European EDs and (2) to identify patient 
groups which might benefit from new biomarkers.
METHODS
Study design
This study is embedded in MOFICHE (Management and 
Outcome of Febrile children in Europe), an observational multi-
centre study, which is part of PERFORM (PErsonalized Risk 
assessment in Febrile illness to Optimise Real- life Management 
across the European Union) ( www. perform2020. org).
Children aged from 0 to 18 years with temperature ≥38.0°C 
or fever <72 hours before ED visit were included. Twelve EDs 
participated in this study: Austria, Germany, Greece, Latvia, 
the Netherlands (n=3), Spain, Slovenia and the UK (n=3).19 
Data were collected for at least 1 year from January 2017 to 
April 2018. Details of the study design have been described 
previously.20
For this study, we selected patients with CRP measurement 
and excluded patients with working diagnosis of urinary tract 
infections after first assessment at the ED.21 To identify IBI at 
the earliest opportunity, we included only the first ED visit for 
patients with IBI who repeatedly visited the ED within the same 
disease episode. Data were analysed according to a statistical 
analysis plan (online supplemental appendix 1).
Collected data included age, sex, comorbidity (chronic condi-
tion expected to last ≥1 year),22 warning signs for identifying 
risk of serious illness (National Institute for Health and Care 
Excellence (NICE))23 (consciousness, ill appearance, work of 
breathing, meningeal signs, focal neurology, non- blanching rash, 
dehydration) and vital signs (heart rate, respiratory rate, oxygen 
saturation, temperature, capillary refill time). We collected 
CRP level (point- of- care or laboratory assay) and microbiologic 
cultures (blood, cerebrospinal fluid and other) ordered at the 
ED or at the first day of hospital admission on indication of the 
physician. Furthermore, we collected data of prescribed antibi-
otics and admission following ED visit.
Outcome
IBI included bacterial meningitis, bacteraemia and bacterial 
bone/joint infections, defined as culture or PCR detection of a 
single pathogenic bacterium in blood, cerebrospinal or synovial 
fluid. All cultures that were treated as contaminant and cultures 
growing contaminants were considered non- IBI (online supple-
mental appendix 2).24 Cultures growing a single contaminant 
or candida were defined positive in patients with malignancy, 
immunodeficiency, immunosuppressive drugs or a central cath-
eter, since antimicrobial treatment is needed in these patients.
Model development
Descriptive and univariate logistic regression analyses were 
performed for children with and without IBI.
Sample size was estimated based on Riley et al.25 Assuming 16 
predictors, a prevalence of 0.8% and an expected R2 of 0.0135 
(15% of maximum achievable R2), a sample size of 10 587 with 
85 cases would be sufficient. For model development,26 27 we 
considered predefined variables with predictive value for IBI: 
(1) variables in the Feverkidstool9 (age, sex, temperature, fever 
duration, tachypnoea and tachycardia defined by Advanced 
Paediatric Life Support,28 oxygen saturation <94%, capillary 
refill ≥3 s, work of breathing, ill appearance and CRP value), 
(2) NICE warnings signs (consciousness, meningeal signs, 
focal neurology, status epilepticus, non- blanching rash)23 and 
(3) complex chronic condition (≥2 body systems, malignancy 
or immunocompromised).22 Consciousness, meningeal signs 
and focal neurology were combined into a composite variable 
abnormal neurology. Linearity of continuous variables was 
assessed using restricted cubic splines. As in the Feverkidstool, 
age was modelled linear piecewise for children aged <1 year and 
>1 year and a logarithmic transformation for CRP was used. 
Outliers were truncated at the 0.01 percentile for temperature 
(35.7°C) and the 0.99 percentile for CRP (215 mg/L) and fever 
duration (8 days).
Variable selection was not influenced by the results of the 
univariate logistic regression analysis, but was performed using 
least absolute shrinkage and selection operator (LASSO), which 
reduces the degree of overfitting by shrinking large regression 
coefficients (detailed methods in online supplemental appendix 
3).29 30 The final model was developed on data from all the 
12 EDs. For the cross- validation, we created 5 ED groups; 1 
group combined the data from the 8 EDs with <10 IBI cases 
and 4 groups were based on data from EDs with >10 IBI cases 
per ED: Slovenia, the Netherlands (n=2) and the UK (online 
supplemental appendix 4). Next, in cross- validation the model 
was repeatedly derived on four ED groups and validated on the 
fifth ED group, leading to five different cross- validations.31 The 
five cross- validations were pooled using a random- effects model. 
This cross- validation determines model performance most accu-
rately and provides information on the heterogeneity of perfor-
mance across different settings. This cross- validation is therefore 
superior to a single external validation.13 31 We assessed the 
4300.7802.430. P
rotected by copyright.
 on D
ecem
ber 8, 2020 at E
rasm
us M
edical / X
51
http://adc.bm
j.com
/
A
rch D
is C
hild: first published as 10.1136/archdischild-2020-319794 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
3Hagedoorn NN, et al. Arch Dis Child 2020;0:1–7. doi:10.1136/archdischild-2020-319794
Original research
discriminative ability by the area under the receiver operating 
curve (AUC), and calibration, the agreement between predicted 
risks and observed cases. We explored the impact of difference in 
case- mix heterogeneity on the discriminative ability of the model 
in the internal- external cross- validation. We used decision curve 
analysis to evaluate the net benefit of the prediction model.32 At 
different cut- offs for the individual probability of IBI according 
to the model, we assessed sensitivity, specificity, negative and 
positive likelihood ratios (LRs) . Missing values for the covari-
ates were multiple imputed using the MICE package, resulting 
in 20 imputation sets (details in online supplemental appendix 
3). Sensitivity analysis was performed in the population where 
missing CRP values were imputed. All analyses were performed 
in R V.3.6.
RESULTS
Of 38 480 patients, 17 213 patients had CRP measurements. 
Patients with CRP measurements were more often ill- appearing 
and admitted than patients without CRP measurements (online 
supplemental appendix 5). We excluded 939 urinary tract infec-
tions and 6 repeated visits in the same disease period of patients 
with IBI, resulting in 16 268 patients. Of those, most common 
infections were the upper respiratory tract (45%), lower respi-
ratory tract (18%), gastrointestinal tract (14%) and undiffer-
entiated fever (9%). IBI was diagnosed in 135 patients (0.8%), 
and comprised 119 bacteraemias, 15 bacterial meningitis and 
9 bone/joint infections (8 patients had concurrent infections). 
Main pathogens included Streptococcus pneumoniae (21%), 
Staphylococcus aureus (19%), Escherichia coli (10%), Neisseria 
meningitidis (7%) and coagulase- negative staphylococcus (7%) 
(figure 1, online supplemental appendix 6). Complex chronic 
conditions were present in 37% of patients with IBI vs 6% of 
patients without IBI. IBI incidence varied from 0.1% to 5.6% of 
patients per ED (online supplemental appendix 4).
Patients with IBI were similar in age and sex compared with 
patients without IBI. CRP level was higher in the IBI group 
(median 62 mg/L, IQR 21–144) than in the non- IBI group 
(median 16 mg/L, IQR 5–45) (p<0.01) (table 1). The majority 
of IBIs were treated with antibiotics (n=126, 93.3%) at first ED 
visit and all were treated with antibiotics in the disease course. 
The associations of the sole predictors with IBI are provided in 
online supplemental appendix 7.
The final model is presented in table 2. This model discrim-
inated well (AUC 0.84 (95% CI 0.81 to 0.88)). In the cross- 
validation, the model discriminated moderate to well (range 
AUC 0.76–0.81) yielding a pooled AUC of 0.78 (95% CI 0.74 
to 0.82) (figure 2). Calibration was poor to moderate for the 
different cross- validations (range slope: 0.45–0.81, range inter-
cept −1.2 to 1.0) (online supplemental appendix 8). Apparent 
calibration was improved by adding an ED- specific variable for 
high (>2%) versus low (<2%) incidence of IBI (online supple-
mental appendix 9).
The diagnostic performance was good for the rule- out 
threshold of 0.1% with sensitivity of 0.97 (95% CI 0.93 to 
0.99) and negative LR of 0.09 (95% CI 0.03 to 0.23) (table 3, 
online supplemental appendix 10). For the rule- in threshold of 
Figure 1 Identified pathogens for invasive bacterial infections (n=135). CoNS, coagulase- negative staphylococci; spp, species.
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Table 1 Characteristics of patients with invasive bacterial infections and patients without invasive bacterial infections
Invasive bacterial infection (n=135) No invasive bacterial infection (n=16 133)
n (%) Missing n (%) Missing
Age in years, median (IQR) 3.2 (0.8–6.0) 2.8 (1.4–6.0)
Female 76 (56.2) 8932 (55.4)
Underlying chronic condition 2 89
  Any 68 (50.4) 3005 (18.6)
  Complex 50 (37.0) 1008 (6.2)
Referred 96 (71.1) 3 8633 (53.5) 936
Triage urgency 5 477
  Low: standard, non- urgent 41 (30.4) 9242 (57.3)
  High: immediate, very urgent, intermediate 89 (65.9) 6414 (39.8)
Feverkidstool
  Temperature in °C, median (IQR) 38.0 (37.4–38.7) 3 37.8 (37.0–38.5) 764
  Fever duration in days, median (IQR) 0.5 (0.5–3) 5 1.5 (0.5–3) 817
  Tachypnoea (APLS) 38 (28.1) 37 3345 (20.7) 3919
  Tachycardia (APLS) 81 (60.0) 5 5578 (34.6) 821
  Hypoxia <95% 4 (2.9) 13 749 (4.6) 2373
  Prolonged capillary refill (>3 s) 8 (5.9) 29 305 (1.9) 2311
  Increased work of breathing 11 (8.1) 40 887 (5.5) 2136
  Ill appearance 60 (44.4) 13 4398 (27.3) 610
  CRP in mg/L, median (IQR) 61 (21–144) 16 (5–45)
NICE warning signs
  Decreased level of consciousness 6 (4.4) 137 (0.8) 141
  Meningeal signs 8 (5.9) 24 116 (0.7) 845
  Focal neurology 2 (1.5) 29 95 (0.6) 1249
  Status epilepticus 0 (0.0) 8 49 (0.3) 887
  Rash: petechiae/non- blanching 10 (7.4) 25 640 (3.9) 1183
Blood cultures performed 134 (99.3) 3002 (18.6)
CSF performed 25 (18.5) 381 (2.4)
Admission to the ward >24 hours 111 (82.2) 1 5879 (36.4) 159
Admission to the ICU 10 (7.4) 125 (0.8) 17
Antibiotic treatment following ED visit 126 (93.3) 5804 (35.9) 197
LSI: airway, breathing or haemodynamic support 16 (11.9) 343 (2.1)
APLS, advanced paediatric life support; CRP, C reactive protein; CSF, cerebrospinal fluid; ED, emergency department; ICU, intensive care unit; LSI, life- saving intervention; NICE, 
National Institute for Health and Care Excellence.
Table 2 Model specification of multivariate logistic model for IBI
Coefficients OR
  (Intercept) −9.16 0.00
Feverkidstool Male −0.19 0.83
  Age <1 year* −2.53 0.08
  Age ≥1 year* 0.00 1.00
  Temperature −0.05 0.95
  Fever duration in days −0.15 0.86
  Tachypnoea −0.44 0.65
  Tachycardia 0.69 2.00
  Hypoxia −0.87 0.42
  Increased work of breathing −0.31 0.73
  Ill appearance 0.87 2.38
  ln CRP 0.76 2.14
NICE warning signs Abnormal neurology 1.54 4.66
  Non- blanching rash 1.38 3.96
Comorbidity Complex chronic condition 2.41 11.1
The risk of children aged <1 year was calculated: β(age <1 year)×age in years.
The risk of children aged ≥1 year was calculated: β(age <1 year)×1+(age in years−1)×β 
(age ≥ 1 in years).
*Age <1 year and age ≥1 year were calculated linear- piecewise.
CRP, C reactive protein; IBI, invasive bacterial infection; ln, natural log.
Figure 2 Discriminative value of the prediction model for invasive 
bacterial infection for five internal- external cross- validations. The 
model was repeatedly derived on four ED groups, and validated on the 
fifth ED group which was left out from the derivation. The five cross- 
validations were pooled using a random- effects model. More details 
are provided in figure A in online supplemental appendix 3. AUC, area 
under the receiver operating curve; ED, emergency department; NL, The 
Netherlands; UK, United Kingdom; UMC, University Medical Centre.
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2.0%, the model had specificity 0.94 (95% CI 0.94 to 0.95) 
and positive LR of 8.4 (95% CI 6.9 to 10.0). The intermediate 
thresholds of 0.1%–2.0% performed poorly (ranges: sensitivity 
0.59–0.93, negative LR 0.14–0.47, specificity 0.52–0.88, posi-
tive LRs 1.9–4.8) and comprised 9784 (60.1%) patients. The 
rule- in threshold misclassified four patients with IBI from three 
different EDs, including two patients with arthritis, and two 
patients with a sinusitis and pneumonia resulting in bacteraemia. 
Three of these patients had CRP levels <10 mg/L and symptoms 
<1 day.
In sensitivity analysis involving the population with imputed 
CRP levels (n=37 093, IBI n=135), model development yielded 
similar coefficients (online supplemental appendix 11).
DISCUSSION
Based on the Feverkidstool and important predictors for early 
recognition of IBI, we derived and cross- validated a clinical 
prediction tool, in febrile children at different European EDs. 
The prediction model discriminated well between patients with 
and without IBI. The risk threshold of 0.1% has good rule- out 
value for IBI and thus decreases the risk of missing an IBI. The 
higher risk thresholds of >2.0% have good rule- in value and 
these thresholds can be used to identify patients at high risk of 
IBI to target treatment. The large number of patients with inter-
mediate risk of 0.1%–2.0% for IBI is expected to benefit most 
from sensitive biomarkers.
Strengths of this study include the participation of 12 Euro-
pean EDs based in 8 countries with a broad population of febrile 
children of all ages and chronic conditions. Furthermore, we 
performed five cross- validations which provided us insight in 
heterogeneity between EDs, and improves the generalisability of 
our results. Second, we included a large number of IBI cases, 
while previous studies did not have sufficient cases to define 
a prediction model exclusively for IBI.9–11 Furthermore, our 
model involves accessible predictors as clinical symptoms and 
CRP level, which will facilitate implementation in practice. We 
provide clinical case examples of the model (online supplemental 
appendix 12) and, to help physicians to use this model in prac-
tice, a web- based digital calculator will be developed.
Our study has some limitations. First, we focused our study 
on patients who had CRP measurement on indication. This 
involved more severe illness than patients without CRP measure-
ment. However, the CRP group reflect patients with diagnostic 
uncertainty and is more likely to benefit from a clinical predic-
tion model. All patients with IBI had CRP measurement, leading 
to inclusion of all eligible IBIs in the main analysis. In our sensi-
tivity analysis, predictors were similar in the model developed 
on imputed CRP levels. Therefore, model performance was 
not influenced by selection of patients with CRP measurement. 
Second, diagnostic tests were ordered according to usual care. If 
patients with an IBI did not have cultures taken >24 hours after 
hospital admission, this was not included in the data and these 
patients could have been misclassified as non- IBI. Since diag-
nostic workup is in general performed at the ED or <24 hours 
after presentation, this misclassification is minimised. Third, 
due to the low incidence of IBI, model performance was eval-
uated in cross- validation with a lower number of cases than is 
optimal for validation (100 cases).33 34Although discrimination 
of the model was good in the cross- validations, calibration was 
poor to moderate. The low incidence of IBI and other case- mix 
differences not taken into account by our model may have influ-
enced model performance in the cross- validation. Our range 
of IBI incidence (range EDs 0.1%–5.6%) was comparable with 
IBI incidence in other studies including febrile population of 
all age ranges (range 0.4%–4.5%).9 11 35 Fourth, due to limited 
measurements of systolic blood pressure (14.7%) and procalci-
tonin in our cohort (1.6%), we were not able to include these as 
predictor. Lastly, data on individual immunisation status were 
not available and were not included in the model. In the clin-
ical assessment of febrile patients, immunisation status should be 
taken into account.
Patients with and without IBI were discriminated well in the 
cross- validations. Calibration was poor to moderate indicating 
discrepancy between model predictions and the observed risk 
of IBI. Addition of the ED covariate of low/high incident IBI 
improved calibration, indicating that model performance is 
influenced by the likelihood of IBI in the ED. Therefore, ED 
incidence should be included in the model.
Clinical prediction models involving older children are the 
Feverkidstool and Irwin’s model, and predict pneumonia and 
other serious bacterial infections separately, whereas our model 
focuses on IBI. Discrimination of our model in cross- validation 
(pooled AUC: 0.78 (95% CI 0.74 to 0.82) was better compared 
with one external validation and similar to another external 
validation of the Feverkidstool for other serious bacterial infec-
tion.9 11 Unlike our study, these models were not based on an 
European- wide ED population. We recommend to use the 
Feverkidstool to guide antibiotic prescription in suspected lower 
respiratory tract infections18 and to use our model in febrile chil-
dren to predict IBI. These two models, the original Feverkidstool 
and our model will be integrated in one electronic decision tool. 
For both implementation of the Feverkidstool and our model, 
measurement of (point- of- care) CRP is necessary. We do not 
recommend CRP measurement in all febrile children, but since 
CRP level is an important discriminator in bacterial and viral 
illness, measurement should be easily accessible to aid in the 
decision- making process at the ED.
Missing and undertreatment of IBI in children can lead to 
morbidity and mortality. Current practice is to start antibiotic 
treatment in patients at risk for bacterial infection awaiting 
Table 3 Diagnostic performance of the prediction model for different risk thresholds for invasive bacterial infection
Risk
thresholds (%) N below threshold (%) N above threshold (%)
Sensitivity
(95% CI)
Negative LR
(95% CI)
Specificity
(95% CI)
Positive LR
(95% CI)
0.1 5495 (33.8) 10 773 (66.2) 0.97 (0.93 to 0.99) 0.09 (0.03 to 0.23) 0.34 (0.33 to 0.35) 1.5 (1.4 to 1.5)
0.2 8461 (52.0) 7807 (48.0) 0.93 (0.87 to 0.96) 0.14 (0.08 to 0.26) 0.52 (0.52 to 0.53) 1.9 (1.9 to 2.1)
0.25 9416 (57.9) 6852 (42.1) 0.90 (0.84 to 0.95) 0.17 (0.10 to 0.28) 0.58 (0.58 to 0.59) 2.2 (2.0 to 2.3)
0.5 12 200 (75.0) 4068 (25.0) 0.76 (0.67 to 0.83) 0.32 (0.24 to 0.44) 0.75 (0.75 to 0.76) 3.1 (2.8 to 3.4)
1.0 14 224 (87.4) 2044 (12.6) 0.59 (0.50 to 0.67) 0.47 (0.39 to 0.58) 0.88 (0.87 to 0.88) 4.8 (4.1 to 5.6)
2.0 15 279 (93.9) 989 (6.1) 0.48 (0.39 to 0.57) 0.55 (0.47 to 0.65) 0.94 (0.94 to 0.95) 8.4 (6.9 to 10)
5 15 831 (97.3) 437 (2.7) 0.36 (0.37 to 0.45) 0.65 (0.57 to 0.74) 0.98 (0.97 to 0.98) 15 (12 to 19)
LR, likelihood ratio.
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culture results which take >48 hours. Since the low incidence 
of IBI, this leads to overuse of antibiotics and resources. The 
balance of not missing IBIs and overtreating self- limiting infec-
tions is delicate. Therefore, clinical prediction models can help 
in decision making at the ED. Our study showed that the low- 
risk threshold can be helpful to rule- out IBI and to reduce inva-
sive diagnostics and antibiotic use.
Starting early treatment is key to prevent adverse outcomes 
due to IBI. The high risk threshold of >2.0% can be used for 
targeted treatment with intravenous antibiotics. Although our 
model was able to identify 38% of the study population as 
low or high risk, diagnostic uncertainty exist for the interme-
diate group (60%). In our study, this intermediate group with 
diagnostic uncertainty was estimated as 25% of the population 
of febrile children presenting to the ED, including patients 
without CRP measurement. Additional diagnostics including 
procalcitonin, repeated CRP measurement36 or novel sensitive 
biomarkers may be helpful in the decision making for this inter-
mediate risk group. The potential benefit of additional diag-
nostics using these risk thresholds will need to be evaluated in 
future studies.
CONCLUSION
Based on the Feverkidstool and important clinical predictors, we 
derived and cross- validated a clinical prediction model for early 
detection of IBI in febrile children in an European- wide cohort. 
Where the rule- in threshold of this model could target early 
treatment to reduce adverse outcomes from IBI, the rule- out 
threshold has the potential to reduce unnecessary use of inva-
sive diagnostics and antibiotics. However, more than half of the 
population was at intermediate risk. In this group, sensitive, new 
biomarkers could improve identification of IBI and could poten-
tially reduce unnecessary antibiotic use.
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